Literature DB >> 7819047

Clomiphene citrate reduces procarbazine-induced sterility in a rat model.

R Weissenberg1, M Lahav, P Raanani, R Singer, A Regev, M Sagiv, S Giler, E Theodor.   

Abstract

Chemotherapy with the cytotoxic drug procarbazine (PCB) causes permanent infertility in most male patients. Since many patients treated with this cytotoxic drug are of reproductive age, it is important to develop a method to protect spermatogenesis and fertility. It has been hypothesised that 'spermatogenic arrest' by pharmacological intervention may render the testes less susceptible to the effects of chemotherapy. The present study investigated whether recovery of fertility in a male rat model could be achieved by suppression of spermatogenesis with high doses of clomiphene citrate (CC) prior to PCB administration. It was demonstrated that young male rats treated with a combination of CC and PCB partially recovered spermatogenesis and achieved almost normal fertility. In contrast, animals treated with PCB alone exhibited abnormal spermatogenesis and remained infertile.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7819047      PMCID: PMC2033459          DOI: 10.1038/bjc.1995.10

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Effects of clompihene on the structure of the testis, epididymis and sex accessory glands of the rat.

Authors:  C J Flickinger
Journal:  Am J Anat       Date:  1977-08

2.  Sterility and testicular atrophy related to cyclophosphamide therapy.

Authors:  K F Fairley; J U Barrie; W Johnson
Journal:  Lancet       Date:  1972-03-11       Impact factor: 79.321

3.  Effect of in vivo and in vitro administration of clomiphene on RNA synthesis in rat testis.

Authors:  M A Hollinger; F Hwang
Journal:  Arch Int Pharmacodyn Ther       Date:  1972-06

4.  Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone.

Authors:  L M Glode; J Robinson; S F Gould
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

5.  Gonadal function in children with nephrosis treated with cyclophosphamide.

Authors:  A J Pennisi; C M Grushkin; E Lieberman
Journal:  Am J Dis Child       Date:  1975-03

6.  Fertility after chemotherapy for testicular cancer.

Authors:  R E Drasga; L H Einhorn; S D Williams; D N Patel; E E Stevens
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

7.  Testicular damage due to cytotoxic drugs and recovery after cessation of therapy.

Authors:  H P Roeser; A E Stocks; A J Smith
Journal:  Aust N Z J Med       Date:  1978-06

8.  The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male.

Authors:  E Whitehead; S M Shalet; G Blackledge; I Todd; D Crowther; C G Beardwell
Journal:  Cancer       Date:  1982-02-01       Impact factor: 6.860

9.  Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations.

Authors:  D H Johnson; R Linde; J D Hainsworth; W Vale; J Rivier; R Stein; J Flexner; R Van Welch; F A Greco
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

Review 10.  Gonadal dysfunction in patients receiving chemotherapy for cancer.

Authors:  R L Schilsky; B J Lewis; R J Sherins; R C Young
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

View more
  3 in total

Review 1.  Hormonal suppression for fertility preservation in males and females.

Authors:  Marvin L Meistrich; Gunapala Shetty
Journal:  Reproduction       Date:  2008-05-30       Impact factor: 3.906

Review 2.  Fertility preservation for boys with cancer.

Authors:  Kazutoshi Fujita; Akira Tsujimura
Journal:  Reprod Med Biol       Date:  2010-08-07

3.  Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage 'in mice.

Authors:  Mattan Levi; Ruth Shalgi; Irit Ben-Aharon
Journal:  Ther Adv Med Oncol       Date:  2022-10-07       Impact factor: 5.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.